Combating complexity: partnerships in personalized medicine
- 1 June 2013
- journal article
- Published by Future Medicine Ltd in Personalized Medicine
- Vol. 10 (4), 387-396
- https://doi.org/10.2217/pme.13.28
Abstract
We are entering an era of unprecedented complexity in personalized medicine. Therapeutic targets, biomarker detection technologies, regulatory and reimbursement pathways, and commercialization strategies have all reached new levels of intricacy. These complexities are occurring in the context of the current economic environment, in which outsourcing offers a way for innovators to decrease large internal investment. These factors combine to create a perfect setting for a partnership explosion. Now, and as we move into the future, it will be critical for innovators to access outside expertise with a diverse set of partners in order to bring novel personalized medicine products to the market successfully and economically. Only companies that truly embrace this trend and adopt a collaborative approach will emerge successful.Keywords
This publication has 14 references indexed in Scilit:
- TGF-β Effects on Prostate Cancer Cell Migration and Invasion Are Mediated by PGE2 through Activation of PI3K/AKT/mTOR PathwayEndocrinology, 2013
- Synergistic Effect of Afatinib with Su11274 in Non-Small Cell Lung Cancer Cells Resistant to Gefitinib or ErlotinibPLOS ONE, 2013
- Extracellular Hsp90 (eHsp90) as the Actual Target in Clinical TrialsInternational Review of Cell and Molecular Biology, 2013
- pH-Responsive Artemisinin Derivatives and Lipid Nanoparticle Formulations Inhibit Growth of Breast Cancer Cells In Vitro and Induce Down-Regulation of HER Family MembersPLOS ONE, 2013
- Microfluidic processor allows rapid HER2 immunohistochemistry of breast carcinomas and significantly reduces ambiguous (2+) read-outsProceedings of the National Academy of Sciences of the United States of America, 2013
- Which drug, and when, for patients with BRAF-mutant melanoma?The Lancet Oncology, 2013
- Quizartinib (AC220) is a potent second generation class III tyrosine kinase inhibitor that displays a distinct inhibition profile against mutant-FLT3, -PDGFRA and -KIT isoformsMolecular Cancer, 2013
- Co-chaperon DnaJC7/TPR2 enhances p53 stability and activity through blocking the complex formation between p53 and MDM2Biochemical and Biophysical Research Communications, 2013
- Targeting PD-1/PD-L1 interactions for cancer immunotherapyOncoImmunology, 2012
- Chipping away at the lung cancer genomeNature Medicine, 2012